Alpha Emitters Market Size Worth $1,464.04 Million By 2032 | CAGR: 13.4%

Alpha Emitters Market Size Worth $1,464.04 Million By 2032 | CAGR: 13.4%

The global alpha emitters market size is expected to reach USD 1,464.04 million by 2032, according to a new study by Polaris Market Research. The report “Alpha Emitters Market Share, Size, Trends, Industry Analysis Report, By Type of Radionuclide (Radium, Actinium, Lead, Bismuth, and Others); By Application; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rapid increase in awareness regarding the potential benefits of the targeted alpha emitter and the surge in the number of patients with several types of cancers like ovarian cancer, pancreatic cancer, melanoma, and lymphoma, coupled with the rising usage of alpha therapy due to its exceptionally high cell-killing ability, are among the prominent factors influencing the global market growth.

The rapid development of new targeting strategies that deliver alpha emitters specifically to cancer cells, which can be achieved by conjugating alpha-emitting isotopes with specific targeting molecules such as antibodies, peptides, or small molecules, enabling more precise delivery of the radiation dose to cancer cells while sparing healthy tissues, has been further creating lucrative growth opportunities soon. For instance, in June 2022, Alpha Tau Medical developed ‘Alpha DaRT” and enrolled 1st patient in its feasibility study to evaluate neo-adjuvant therapy for patients who have prostate cancer.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

The growing penetration of automation as an important technological development in alpha emitters, particularly in the production of radiopharmaceuticals, has been pushing the market forward. The use of automated systems for labeling molecules with alpha emitters has made the production of radiopharmaceuticals faster and more efficient, allowing for larger-scale production and lower costs, due to which patients would be able to get access to these therapies more easily or conveniently.

Furthermore, researchers worldwide are exploring the use of combination therapies that combine alpha emitters with other cancer treatments, such as chemotherapy, immunotherapy, or radiation therapy, that could potentially enhance the efficacy of cancer treatments and reduce side effects.

Alpha Emitters Market Report Highlights

  • Radium segment accounted for largesrt market share in 2022, which is mainly driven by rising penetration as a superior cancer treatment due to beneficial properties like minimizing the narrow toxicity
  • Ovarian cancer segment is projected to grow at healthy CAGR during the anticipated period, mainly due to increasing new cases worldwide and adoption as an effective alternative to ovarian carcinoma
  • North America region led the industry market with substantial market share in 2022, owing to presence of several favorable government regulations and highly developed healthcare infrastructure across the region
  • The global key market players include IBA Radiopharma Solution, Telix Pharmaceuticals, Novartis, Fusion Pharmaceuticals, Orano Group, Cardinal Health, and Bayer

Polaris Market Research has segmented the alpha emitters market report based on type of radionuclide, application, and region:

Alpha Emitters, Type of Radionuclide Outlook (Revenue - USD Million, 2019 - 2032)

  • Radium
  • Actinium
  • Lead
  • Bismuth
  • Others

Alpha Emitters, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Pancreatic Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Lymphoma
  • Melanoma
  • Bone Metastasis
  • Others

Alpha Emitters, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Alpha Emitters Market Report Scope

Report Attributes


Market size value in 2023

USD 471.73 million

Revenue forecast in 2032

USD 1,464.04 million


13.4% from 2023 – 2032

Base year


Historical data

2019– 2021

Forecast period

2023 – 2032

Quantitative units

Revenue in USD million and CAGR from 2023 to 2032

Segments covered

By Type of Radionuclide, By Application, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Bayer AG, IBA Radiopharma Solution, Actinium Pharmaceutical Inc., RadioMedix Inc., Alpha Tau Medical Ltd., Telix Pharmaceuticals Ltd., Novartis AG, Fusion Pharmaceuticals, Orano Group, Cardinal Health, The Institute of Radioelements, Nordion Inc., SHINE Medical Technologies, Global Medical Solutions, Isotopia Molecular Imaging Limited, and America Elements.

For Specific Research Requirements

Request for Customized Report

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing